While admittedly our number of matched BBB and tumors is limited, the data from these specimens suggests that, later in oncogenesis, mutations in ATR pathway members, i.e., ATR and ETAA1, are being selected for as they observed in both the benign biopsy and its matched tumor. This evidence concerns the gene ETAA1 and neoplasm.